Merck KGaA, Darmstadt, Germany to Expand US Biopharmaceutical R&D Facility to Advance Innovative Clinical Pipeline

Merck KGaA, Darmstadt, Germany today announced a $70 million investment to expand its state of the art research and development (R&D) facility in Billerica, Massachusetts.

06 Feb 2019 | Billerica, Massachusetts, United States of America
  • Merck KGaA, Darmstadt, Germany investing $70 million in U.S. Research & Development Hub
  • Expansion of R&D footprint to accelerate science and innovation in Oncology, Immuno-oncology and Immunology globally

BILLERICA, Mass., February 6, 2019 -- Merck KGaA, Darmstadt, Germany, which operates its biopharmaceutical business as EMD Serono in the U.S. and Canada, today announced a $70 million investment to expand its state of the art research and development (R&D) facility in Billerica, Massachusetts. The new building will span 145,000 square feet, offering new laboratory and collaborative working space to accommodate approximately 400 new and current R&D employees focused on advancing science in oncology, immuno-oncology and immunology.

"Our talented and passionate R&D teams based in Billerica have been highly engaged in advancing a number of pipeline compounds,” said Luciano Rossetti, MD, Global Head of R&D for the biopharma business of Merck KGaA, Darmstadt, Germany. “We continue to strengthen our innovation footprint in both the U.S. and Darmstadt, Germany where our global R&D headquarters are located, with the goal of delivering transformational value to patients around the world.”

With this latest project, Merck KGaA, Darmstadt, Germany will have invested more than $150 million in infrastructure to advance biopharmaceutical R&D in the state of Massachusetts in recent years, with more than 150 new jobs added to its growing U.S. R&D Hub in Billerica since 2011. The town of Billerica played a critical role in bringing this latest building expansion project to fruition, working collaboratively with Company officials to underscore the benefits of expanding the state-of-the-art R&D facility.

"Merck KGaA, Darmstadt, Germany’s continued investment in Massachusetts is a testament to the state’s global leadership in life sciences," said Travis McCready, President and CEO of the Massachusetts Life Sciences Center. “In working collaboratively with the town of Billerica, the company’s campus expansion over the past decade has not only helped attract and retain top talent in the area, but more importantly, contributed to improving the lives of people with serious medical needs.”

When construction is completed in 2021, the building will offer wet labs, office space and a cafeteria for the campus. Consistent with previous projects, the building will be constructed to the highest environmental and employee wellness standards by seeking LEED and WELL certifications. LEED® is a preeminent program for the design, construction and operation of high-performance green buildings. WELL is a building standard focused on enhancing people's health and wellness through built environments.

The healthcare business of Merck KGaA, Darmstadt, Germany employs approximately 3,500 R&D professionals across four global R&D hubs: Darmstadt, Germany; Boston, U.S.; Tokyo, Japan; and Beijing, China. Merck KGaA, Darmstadt, Germany invests approximately 20% of total sales in R&D discovery and development each year.

Merck KGaA, Darmstadt, Germany’s U.S. presence is comprised of three businesses – Healthcare, Life Science and Performance Materials – with nearly 10,000 employees working in R&D, manufacturing and corporate roles across almost 60 sites country-wide. Within the state of Massachusetts, more than 2,800 professionals work across 10 locations.

Downloads

For more information, please contact Amber Chase

Related News

  1. Press Releases

    Merck KGaA, Darmstadt, Germany, Commissions Fully Automated Unit for the Digital ...

    Merck KGaA, Darmstdt, Germany, today commissioned its first fully automated unit for the digital color measurement of its pigment products.

    2022/09/28